SIGN-UP
Participate in
Research
Our team of professionals are trained to conduct clinical trials for people who want to quit smoking.
Our trials test medications, behavioral approaches and various combinations of both in an attempt to find the most effective smoking cessation treatment. Our staff is also trained to conduct behavioral counseling.
The BuZonE RCT Study
The main purpose of this research study is to see if taking a combination of zonisamide and bupropion for a short time helps you switch to using only an e-cigarette. Zonisamide is a drug approved by the United States Food and Drug Administration (FDA) for treatment of seizures. Bupropion (also known as Zyban) is a drug approved by the FDA for use as an aid to quit smoking (but not for switching from combustible cigarettes to e-cigarettes). The use of the combination of zonisamide and bupropion is not FDA approved for the purpose of switching from combustible cigarettes to e-cigarette use and is therefore considered investigational for this study.
BuZonE RCT FAQ
- Between 22-65 years old
- Desire to switch to an e-cigarette
- Willingness to take study medications as directed
- Currently smoke 10 or more cigarettes per day
- Able to pass a urine drug test
- No current serious medical conditions
- No use of other tobacco products in the last 14 days
- Lives within driving distance of our offices in Raleigh or Charlotte, NC
CYCLE FAQ
- Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English
- Between 22-65 years old
- Interested in switching to an electronic cigarette
- Willing to take study medication
- Currently smoke 10 or more cigarettes per day
- Not pregnant, nursing, or planning to become pregnant
- No current serious medical conditions
- Able to pass a urine drug screen
- Not using other tobacco products in the last 14 days
- Lives within driving distance of our offices in Raleigh or Charlotte, NC
The CYCLE Study
The purpose of the CYCLE research study is to explore ways to help smokers transfer their addiction to nicotine from burning cigarettes to a non-combustible alternative nicotine product. The study will try to find out if d-cycloserine (DCS) can help with transferring nicotine dependence from cigarettes to e-cigarettes. During this study you will be taking 100 mg of d-cycloserine daily to see if it helps you switch to using only an e-cigarette. DCS is a drug approved by the United States Food and Drug Administration (FDA) for treatment of tuberculosis. The use of DCS is not FDA approved for the purpose of switching from combustible cigarettes to e-cigarette use and is therefore considered investigational for this study.
The Adaptive 2 Study
The main purpose of this study is to see if smokers who respond early to alternative nicotine products can successfully maintain their smoking reduction by continues use of these noncombustible nicotine alternatives for up to 6 months. These alternative nicotine products include nicotine gum, nicotine lozenges, nicotine patches, oral nicotine pouches, or e-cigarettes.
Adaptive 2 FAQ
- Between 22-65 years old
- Not pregnant, nursing, or planning to become pregnant
- Has a smartphone with iOS 16+ or Android 13+
- Currently smoke 10 or more cigarettes per day
- No current serious medical conditions
- No use of other tobacco products
- Lives within driving distance of our office in Raleigh, NC
AUS FAQ
- Between 22-65 years old
- Not pregnant, nursing, or planning to become pregnant
- Has a smartphone with iOS 12.4+ or Android 12+
- Currently smokes cigarettes daily
- No current serious medical conditions
- No known allergies or sensitivities to any ingredients found in e-cigarette products or any of the components in e-liquids (nicotine, flavor, benzoic acid, propylene glycol and glycerol, menthol, peppermint oil)
- Lives within driving distance of our offices in Raleigh, or Charlotte, NC
The AUS Study
The main purpose of this Study is to better understand how adult smokers use the Study Product and how they feel about it. The Study Product has been developed by Juul Labs, Inc. (“the Sponsor”), to provide adult smokers with an alternative to cigarette smoking.
SIGN-UP
For Future
Studies
Fill out our form below for more information
Participant information is maintained in a volunteer database system and retained for future studies as they become available. Pertinent information is confidentially kept on file to aid in selecting highly qualified candidates for research studies.
Why should I participate?
Participants may gain access to new research treatments before they are widely available.
Additionally, participants are compensated for their time and receive study-related products and medications at no cost. You may be among the first to benefit if the approach being studied is found to be helpful.